Clovis Oncology Inc(NASDAQ:CLVS) dropped following the release of updated data from Phase 1 and early Phase 2 of CO-1686, which showed 22% of patients developed hyperglycemia and required a prescription to manage this symptom. Clovis Oncology Inc (NASDAQ:CLVS) weekly performance is -26.17%. On last trading day company shares ended up $38.23. Analysts mean target price for the company is $98.63. Clovis Oncology Inc (NASDAQ:CLVS) distance from 50-day simple moving average is -34.71%.
Prosensa Holding N.V. (NASDAQ: RNA) announced that the FDA has outlined a regulatory path forward, under an accelerated approval pathway, for drisapersen, the Company’s lead program for the potential treatment of Duchenne Muscular Dystrophy (DMD). In addition, the company has been interacting with the European Medicines Agency (EMA) and based on these interactions intends to file in Europe as well. Prosensa Holding NV (NASDAQ:RNA) shares fell -5.76% in last trading session and ended the day on $9.98. RNA its return on assets is -7.50%. Prosensa Holding NV (NASDAQ:RNA) quarterly performance is 53.78%.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced that Chief Executive Officer Mark Baker will present on Thursday, June 5th, at 10:00 AM EDT at the Jefferies Global Healthcare Conference in New York City. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares moved down -6.20% in last trading session and was closed at $3.63, while trading in range of $3.54-$3.80. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) year to date performance is -31.89%.
Robert W. Baird cut shares of Theravance Inc (NASDAQ:THRX) from an outperform rating to a neutral rating in a research report sent to investors on Monday morning. Theravance Inc (NASDAQ:THRX) ended the last trading day at $23.10. Company weekly volatility is calculated as 4.38% and price to cash ratio as 7.02. Theravance Inc (NASDAQ:THRX) showed a negative weekly performance of -19.57%.
Zalicus Inc (NASDAQ:ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, announced that it has closed the sale of its combination High Throughput Screening (cHTS) platform and related assets to Horizon Discovery Group for $8 million plus certain additional amounts relating to the working capital of these assets. Zalicus Inc (NASDAQ:ZLCS) weekly performance is 1.75%. On last trading day company shares ended up $0.987. Analysts mean target price for the company is $1.20. Zalicus Inc (NASDAQ:ZLCS) distance from 50-day simple moving average is -11.34%.